News Sentiment

INTS sentiment intelligence

Intensity Therapeutics, Inc. Common stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 65 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.78 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 58

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+12.7% over one week, +32.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Intensity Therapeutics restarts 61-patient breast cancer trial

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction 12.7% Price confirming higher
Trend fit Trend inactive 32.0% over four weeks
Fair value -92.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 40
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 58
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
TradingView 10
Market source 9
PR Newswire 6
Stock Titan 6
TradingKey 5
Investing.com 3
grafa.com 2
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 22
Analyst action 4
Regulatory and legal 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 65
Quiver Quantitative Direct company coverage

INTS | Intensity Therapeutics, Inc. Common Insider Trading

This article provides an overview of Intensity Therapeutics, Inc. (INTS) stock information, focusing on insider trading, institutional holdings, and other financial data available through Quiver Quantitative. It details the absence of recent congressional or quarterly net insider

Tone
Neutral 50/100
Event
Market update
Published
30 May 2026 07:39
Source
Quiver Quantitative
Investing.com Direct company coverage

Benchmark reiterates Intensity Therapeutics stock rating on clinical progress

Benchmark has maintained a "Speculative Buy" rating and a $12.00 price target for Intensity Therapeutics (NASDAQ:INTS) after the company's first-quarter results and clinical updates. The biotechnology firm received approval to resume enrollment in trials for its INT230-6 treatmen

Tone
Positive 71/100
Event
Analyst action
Published
20 May 2026 14:39
Source
Investing.com
Stock Titan Direct company coverage

Biotech behind INT230-6 honored for novel tumor-killing approach

Intensity Therapeutics (Nasdaq: INTS) has been named Cancer Treatment Technology Innovator of the Year 2026 – USA by GHP Magazine for its proprietary intratumoral cancer therapies. The award recognizes the company's non-covalent drug-conjugation platform, which has shown encourag

Tone
Positive 74/100
Event
Market update
Published
18 May 2026 09:38
Source
Stock Titan
ChartMill Direct company coverage

INTS News | INTENSITY THERAPEUTICS INC (NASDAQ:INTS)

This article provides recent news and analysis for Intensity Therapeutics Inc. (NASDAQ: INTS). Key updates include the company's Q1 2026 results where EPS beat expectations despite no revenue, and its recognition with GHP Magazine's 2026 Healthcare & Pharmaceutical Award. The cur

Tone
Positive 66/100
Event
Earnings
Published
18 May 2026 08:39
Source
ChartMill